Compare Ascendis Pharma A/S (ASND) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs MobilEye Global Inc — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while MobilEye Global Inc trades at $9.65 (market cap $8.04B). The key difference: Ascendis Pharma A/S is far larger — about 2.2× MobilEye Global Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| ASND | MBLY | |
|---|---|---|
Market Cap | $17.74B | $8.04B |
Sector | Health | Technology |
52-Week High | $277.18 | $16.57 |
52-Week Low | $163.32 | $6.56 |
Enterprise Value | $18.11B | $6.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Mobileye (MBLY) trades at $9.55, up 0.21% with a bullish technical signal. The company shows strong revenue growth ($1.89B in 2025) but significant net losses (-$392M). Recent earnings beat expectations in Q1 2026, while analysts maintain a 57.69% buy rating with a $10.36 consensus target. The stock faces pressure from negative profitability metrics but benefits from positive sentiment around its 2027 robotaxi launch plans.
MBLY presents a high-risk opportunity with transformative potential through autonomous driving technology. The upcoming robotaxi business could drive long-term growth, but current financial losses and competitive pressures require careful monitoring. Investor sentiment remains cautiously optimistic pending execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
